GeoVax Labs (NASDAQ:GOVX) Price Target Cut to $6.00 by Analysts at D. Boral Capital

GeoVax Labs (NASDAQ:GOVX) had its target price cut by equities researchers at D. Boral Capital from $9.00 to $6.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $7.50.

GeoVax Labs Price Performance

NASDAQ:GOVX opened at $0.41 on Wednesday. The firm has a 50-day moving average of $0.58 and a two-hundred day moving average of $0.75. The stock has a market cap of $12.12 million, a P/E ratio of -0.20 and a beta of 3.34. GeoVax Labs has a 1-year low of $0.40 and a 1-year high of $3.15.

GeoVax Labs (NASDAQ:GOVX) last announced its earnings results on Thursday, November 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.07). GeoVax Labs had a negative return on equity of 408.80% and a negative net margin of 403.88%. As a group, equities analysts expect that GeoVax Labs will post -4.49 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Armistice Capital LLC acquired a new position in shares of GeoVax Labs in the 1st quarter worth approximately $703,000. Sabby Management LLC acquired a new stake in shares of GeoVax Labs during the 3rd quarter valued at approximately $313,000. Finally, Jane Street Group LLC bought a new position in GeoVax Labs during the first quarter worth $27,000. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.